NCT02466685View on ClinicalTrials.gov

Testing the Ability of JNJ-18038683 to Improve Cognition and Reduce Depressive Symptoms in Stable Bipolar Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

September 30, 2021

Study Completion Date

December 31, 2022

Conditions
Bipolar Disorder
Interventions
DRUG

JNJ-18038683

JNJ-18038683 10-20 mg/day tablet for 8 weeks

DRUG

Placebo

placebo tablet daily

Trial Locations (1)

60611

Northwestern University Feinberg School of Medicine; Department of Psychiatry and Behavioral Sciences, Chicago

All Listed Sponsors
collaborator

Janssen Research & Development, LLC

INDUSTRY

lead

Herbert Meltzer

OTHER

NCT02466685 - Testing the Ability of JNJ-18038683 to Improve Cognition and Reduce Depressive Symptoms in Stable Bipolar Patients | Biotech Hunter | Biotech Hunter